Estratest Shortage Update: What Patients Need to Know in 2026

Patients who rely on Estratest — or its generic equivalents EEMT and Covaryx — have been dealing with availability challenges for years. In 2026, the situation remains frustrating: the medication is not on the FDA's official shortage list, but many patients continue to struggle to fill their prescriptions at local pharmacies.

This article provides a current status update and explains the factors driving the ongoing supply challenges — so you can be better prepared.

Current Status: Is Estratest in a Formal Shortage in 2026?

As of 2026, esterified estrogens/methyltestosterone (EEMT) is not listed as an active shortage on the FDA's official drug shortage database. The drug does remain legally available as a generic product through multiple manufacturers.

However, "not in a formal shortage" does not mean "easy to find." Patients consistently report that their usual pharmacies — including major chains like CVS, Walgreens, and Walmart — are often out of stock. This is an intermittent, regional availability problem rather than a complete market withdrawal. The drug exists; it's just unevenly distributed.

A Brief History: Why Did Estratest Become Hard to Find?

To understand today's availability problems, it helps to trace the drug's history:

1964–1965: Esterified estrogens/methyltestosterone first marketed in the U.S. by Reid-Provident Laboratories under the Estratest brand.

1986: Solvay Pharmaceuticals acquired the product by purchasing Reid-Rowell, Inc.

Pre-2009: FDA raised concerns about whether the androgen component actually contributed to effectiveness for vasomotor symptoms. The National Women's Health Network petitioned the FDA to withdraw the drug.

March 2009: Solvay announced it would discontinue Estratest and Estratest H.S., citing business factors. New orders stopped on March 31, 2009. This left patients scrambling for alternatives.

2009–present: Generic manufacturers stepped in to supply esterified estrogens/methyltestosterone under names like Covaryx, EEMT, and Syntest. However, the number of active manufacturers has remained small, and supply has been inconsistent.

June 2020: DEA designated certain esterified estrogens/methyltestosterone combination products as exempt from Schedule III control, which helped reduce some regulatory burden on specific manufacturers.

What Is Driving Ongoing Availability Problems in 2026?

Several structural factors continue to make this medication harder to find than it should be:

Small manufacturer base: Only a handful of generic manufacturers produce this drug. Any disruption — raw material shortage, manufacturing issue, or business decision — affects the entire market.

Controlled substance regulations: The methyltestosterone component still subjects some formulations to DEA oversight, adding compliance requirements across the supply chain.

Low stocking priority: Because EEMT serves a smaller patient population than blockbuster drugs, pharmacies give it lower priority. If their wholesaler runs low, it may not get reordered promptly.

Regulatory uncertainty: This medication has never been approved through the modern FDA New Drug Application process, which means it operates in a gray zone that some pharmacies and insurers treat with extra caution.

Impact on Patients: What Are People Experiencing?

Patients dealing with EEMT unavailability report:

Calling 5 or more pharmacies before finding stock

Month-to-month inconsistency even at pharmacies that usually carry it

Return of hot flashes and night sweats during supply gaps

Confusion between different generic names (EEMT vs. Covaryx vs. Estratest)

Being told to switch to a different medication without being given alternatives information

What Can Patients Do Right Now?

Here are the most effective steps for patients dealing with this situation:

Use medfinder: medfinder.com calls pharmacies near you to check which ones currently have your medication in stock — saving you hours of phone calls.

Ask for all generic names: Ask pharmacies for EEMT, EEMT HS, Covaryx, Covaryx HS, and esterified estrogens/methyltestosterone — not just Estratest.

Call ahead before you run out: Start your search at least a week or two before running out to give yourself time to locate stock or place an order.

Talk to your prescriber: If supply is genuinely unavailable near you, discuss alternatives with your OB/GYN or menopause specialist. Never stop hormone therapy abruptly.

Consider mail-order: Your insurance plan's mail-order pharmacy may have a more reliable supply of EEMT than local retail pharmacies.

The Bottom Line

Estratest and its generics are not in a formal FDA shortage in 2026, but supply remains inconsistent and patients continue to face real challenges filling their prescriptions. The reasons are structural — small manufacturer base, regulatory complexity, niche patient population — and unlikely to fully resolve in the near term. Being proactive, knowing all the generic names, and using tools like medfinder are your best defenses. If you're considering a switch, see our guide to alternatives to Estratest for a full comparison.